Skip to main content
The University of Arizona Wordmark Line Logo White
Stories & Features Announcements Calendar Leadership Updates Event Planning Room Scheduling Café Bolo Directories IT Support Classroom Support Planning & Facilities
The University of Arizona Health Sciences | Home
Subscribe
Support
home home

Main navigation

  • Overview Senior Leadership Academic Leadership Executive Leadership Annual Report Mission, Values, History Support
  • Overview College of Health Sciences College of Medicine – Phoenix College of Medicine – Tucson College of Nursing Mel and Enid Zuckerman College of Public Health R. Ken Coit College of Pharmacy
  • Research Administration Research Awards and Grants
  • Clinical
  • Overview Community Engagement Alliance Corporate and Community Relations Health and Humanities Rural Health Community Events Student Engagement and Career Advancement
  • Overview Aegis Consortium All of Us Research Program Arizona Area Health Education Centers Arizona Simulation Technology & Education Center Asthma & Airway Disease Research Center Center for Accelerated Biomedical Innovation Center for Advanced Molecular & Immunological Therapies Center for Biomedical Informatics & Biostatistics Center for Disparities in Diabetes, Obesity & Metabolism Center for Innovation in Brain Science Center for Sleep, Circadian & Neuroscience Research Clinical & Translational Sciences Research Center Comprehensive Center for Pain & Addiction Health Sciences SensorLab One Health University of Arizona Cancer Center
  • All News Stories Videos The Healthy Dose Blog News Releases In The Media Media Resources Office of Communications
  1. Home
  2. Node

SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study

Read more about SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study

Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)

Read more about Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

Read more about CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

An Open-label, Controlled, Randomized Phase 3 Trial Evaluating 12-month Kidney Function in Highly Sensitized (cPRA > 99.9%) Kidney Transplant Patients With Positive Crossmatch Against a Deceased Donor

Read more about An Open-label, Controlled, Randomized Phase 3 Trial Evaluating 12-month Kidney Function in Highly Sensitized (cPRA > 99.9%) Kidney Transplant Patients With Positive Crossmatch Against a Deceased Donor

A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of KER-012 in Combination with Background Therapy in Adult Participants with Pulmonary Arterial Hyp

Read more about A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of KER-012 in Combination with Background Therapy in Adult Participants with Pulmonary Arterial Hyp

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Delay of Encephalopathy Decompensation i

Read more about A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Delay of Encephalopathy Decompensation i

A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pln-74809 (Bexotegrast) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF)

Read more about A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pln-74809 (Bexotegrast) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF)

A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment in Premenopausal Women with ER+/HER2- Breast Cancer

Read more about A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment in Premenopausal Women with ER+/HER2- Breast Cancer

A Phase 2b, Multinational, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Redasemtide (S-005151) Compared With Placebo in Adult Participants With Acute Ischemic Stroke Who Ar

Read more about A Phase 2b, Multinational, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Redasemtide (S-005151) Compared With Placebo in Adult Participants With Acute Ischemic Stroke Who Ar

A Phase 1b Study of the OxPhos Inhibitor ME-344 Combined With Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Read more about A Phase 1b Study of the OxPhos Inhibitor ME-344 Combined With Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Pagination

  • « First First page
  • ‹ Previous Previous page
  • …
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • Next › Next page
  • Last » Last page
Subscribe to
The University of Arizona Health Sciences | Home

Health Sciences

  • About
  • Academics
  • Research
  • Centers and Programs
  • Clinical Care
  • Outreach
  • Initiatives

News

  • Stories
  • Healthy Dose Blog
  • News Releases
  • In The Media
  • Media Resources
  • Videos

Internal Resources

  • Stories & Features
  • Announcements
  • Calendar
  • Leadership Updates
  • Honors and Awards
  • Event Planning
  • Room Scheduling
  • Café Bolo
  • El Mirador Project
  • IT Support
  • Classroom Support
  • Planning and Facilities
  • Photo Galleries
  • Directories

Connect

  • Facebook
  • YouTube
  • Instagram
  • LinkedIn
  • X, formerly Twitter

We respectfully acknowledge the University of Arizona is on the land and territories of Indigenous peoples. Today, Arizona is home to 22 federally recognized tribes, with Tucson being home to the O’odham and the Yaqui. The university strives to build sustainable relationships with sovereign Native Nations and Indigenous communities through education offerings, partnerships, and community service.


University Information Security and Privacy

© 2025 The Arizona Board of Regents on behalf of The University of Arizona.